NTLA
NTLA clinical trials: Intellia Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Intellia Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 9
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
NTLA on the catalyst calendar · NTLA registry changes
- Primary completion Jul 2027Sponsor estimatePhase 3NCT06672237A Phase 3 Study of NTLA-2001 in ATTRv-PNIntellia Therapeutics · Neuromuscular DiseaseActive, not recruitingNTLALeadREGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 3NCT06128629MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)Intellia Therapeutics · Transthyretin Amyloidosis (ATTR) With CardiomyopathyRecruitingNTLALeadREGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 10, 2026ActualPhase 3NCT06634420HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)Intellia Therapeutics · Hereditary AngioedemaActive, not recruitingNTLALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 4, 2024ActualPhase 1/Phase 2NCT05120830NTLA-2002 in Adults With Hereditary Angioedema (HAE)Intellia Therapeutics · Hereditary AngioedemaActive, not recruitingNTLALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2038Sponsor estimateNo phase registeredNCT05697861Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001Intellia Therapeutics · Transthyretin-Related (ATTR) Familial Amyloid PolyneuropathyEnrolling by invitationNTLALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 12, 2025ActualPhase 1NCT04601051Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin...Intellia Therapeutics · Transthyretin-Related (ATTR) Familial Amyloid PolyneuropathyCompletedNTLALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2040Sponsor estimateNo phase registeredNCT06262399Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002Intellia Therapeutics · Hereditary AngioedemaEnrolling by invitationNTLALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 9, 2025Sponsor estimatePhase 1/Phase 2NCT06622668NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung DiseaseIntellia Therapeutics · Lung DiseaseWithdrawnNTLALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 21, 2022ActualPhase 1/Phase 2NCT05066165Study Investigating NTLA-5001 in Subjects With Acute Myeloid LeukemiaIntellia Therapeutics · Acute Myeloid LeukemiaTerminatedNTLALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 14, 2034Sponsor estimatePhase 1/Phase 2NCT06379789A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric...Regeneron Pharmaceuticals · Hemophilia BRecruitingREGNLeadNTLACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner